Site is Being Upgraded

An omega-3 way to treat pain:  PUFA-based activation of the PD-1 pathway for Pain therapy:  ω-PUFAs (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA) increase the expression of PD-L1, attenuate acutes and chronic pain, suppress mechanical and thermal hypersensitivity and inhibit nociceptive neuron excitability, via up-regulation of its target gene, 9/April/2018, 6.31 am

Taurine-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Taurine, an amino sulfonic acid,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 8/April/2018,  12.08 am
April 7, 2018
Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing  Calcitriol, Mitoxantrone, Despiramine, 17DMAG, Salinomycin, Lovastatin, and Jasmonate inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 10/April/2018, 6.05 pm
April 10, 2018
Show all

Introduction:What they say:

A recent study from Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, China; and Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, US, shows that “PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.” This study was published, in the 22 May 2017 issue of Nature Neuroscience (one of the best journals in Neurobiology with an impact factor of 16.724+), by Prof Ji RR, Chen G and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: An omega-3 way to treat pain:  PUFA-based activation of the PD-1 pathway for Pain therapy:  ω-PUFAs (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA) increase the expression of PD-L1, attenuate acutes and chronic pain, suppress mechanical and thermal hypersensitivity and inhibit nociceptive neuron excitability, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year. However, the work published recently, which is described below, may highlight the caveat in such an approach, as blocking PD-L1 may promote spontaneous pain and allodynia in cancer-bearing mice.

Prof. Ji has shown recently that: (1) Programmed cell death ligand-1 (PD-L1), produced by melanoma and normal neural tissues, inhibits acute and chronic pain; (2) injection of PD-L1 alleviates pain, and thereby functions as an analgesic agent; (3) Neutralization of PD-L1 or Block of PD1 promotes mechanical allodynia (hypersensitivity to pain); (4) PD1 null mice suffers from thermal and mechanical hypersensitivity; (5) PD-L1 promotes phosphorylation of SHP-1 and inhibits Sodium channels via PD-1 activation; and (6) PD-L1 inhibits nociceptive neuron excitability in dorsal root ganglion and thereby functions as a neuromodulator, suggesting that increasing the expression or the level of PD-L1/PD1 may alleviate pain and thermal and mechanical hypersensitivity.


From research findings to therapeutic opportunity:

This study suggests, for the first time, an Omega-3 poly unsaturated fatty acid (PUFA)-based therapy for acute and chronic pain. ω-PUFAs (DHA+EPA), by increasing the expression of their target genes, they may increase PD-L1 levels (figs. 1-2). Thereby, they may: (a) inhibit acute and chronic pain; (b) alleviate thermal and mechanical hypersensitivity; (c) activate signal transduction cascade downstream of PD-1 receptor; (c) phosphorylate SHP-1; (d) inhibit sodium channels and nociceptive neuron excitability.

Figure 1.Mechanistic insights into how ω-PUFAs inhibit acute and chronic pain. ω-PUFAs enhance PD-L1 levels, suppress thermal and mechanical hypersensitivity, phosphorylate SHP-1, inhibit activation of sodium channels, and alleviate nociceptive neuron excitability

Figure 2. The chemical structure of ω-PUFAs.   ω-PUFAs may attenuate pain through induction of PDL1.

Thus, pharmacological formulations encompassing ω-PUFAs (DHA+EPA) or their analogues, either alone in combination with other drugs,” may be used to attenuate short-term and long-term pain.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed mechanistic information: How  ω-PUFAs increase the expression of PD-L1

# Research cooperation


References:

Citation: Boominathan, L., An omega-3 way to treat pain:  PUFA-based activation of the PD-1 pathway for Pain therapy:  ω-PUFAs (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA) increase the expression of PD-L1, attenuate acutes and chronic pain, suppress mechanical and thermal hypersensitivity and inhibit nociceptive neuron excitability, via up-regulation of its target gene, 9/April/2018, 6.31 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.